Better Mycophenolic Acid 12-Hour Trough Level After Enteric-Coated Mycophenolate Sodium in Patients With Gastrointestinal Intolerance to Mycophenolate Mofetil

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2194-2196

  Sanchez Fructuoso A ^a   Calvo, N ^a   Moreno, M A ^a   Giorgi, M ^a   Conesa, J ^a   Barrientos, A ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERIC COATED TABLET; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

CREATININE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; METABOLIC CLEARANCE RATE; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; TABLETS, ENTERIC-COATED;

EID: 34548680309     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.033     Document Type: Article

References (12)

1. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61 (1996) 1029
2. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results form the placebo- controlled trial. Transplantation 68 (1999) 391
3. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 34 (1999) 296
4. Ojo A.O., Meier-Kriesche H.U., Hanson J.A., et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69 (2000) 2405
5. Meier-Kriesche H.U., Ojo A.O., Leichtman A.B., et al. Effect of mycophenolate mofetil on long-term outcomes in African american renal transplant recipients. J Am Soc Nephrol 11 (2000) 2366
6. Meier-Kriesche H.U., Steffen B.J., Hochberg A.M., et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 75 (2003) 1341
7. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 17 (2003) 200
8. Knoll G.A., MacDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381
9. Hardinger K.L., Brennan D.C., Lowell J., et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 17 (2004) 609
10. Bjarnason I. Enteric coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc 33 (2001) 3238
11. Borrows R., Chusney G., Loucaidou M., et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 6 (2006) 121
12. Calvo N., Sanchez-Fructuoso Al., Conesa J., et al. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium. Transplant Proc 38 (2006) 2396